Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy

Respiratory Medicine

Volumn 103, Issue 10, 2009, Pages 1532-1539

  Campos, Michael A ^a   Alazemi, Saleh ^a   Zhang, Guoyan ^b   Wanner, Adam ^a   Salathe, Matthias ^a   Baier, Horst ^a   Sandhaus, Robert A ^c,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Miami Dade Health Department   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d AlphaNet   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Exacerbations; Health related quality of life; Lung diseases; Obstructive

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SMOKING;

EID: 69349090395     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.04.008     Document Type: Article

References (27)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (GOLD). Available at: (2006). www.goldcopd.org [accessed 7.17.07]
2. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 10 (2002 Oct) 847-852
3. Seemungal T.A., Donaldson G.C., Bhowmik A., Jeffries D.J., and Wedzicha J.A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 5 (2000 May) 1608-1613
4. Miravitlles M., Ferrer M., Pont A., Zalacain R., Alvarez-Sala J.L., Masa F., et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59 5 (2004 May) 387-395
5. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., and Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 5 Pt 1 (1998 May) 1418-1422
6. Foster T.S., Miller J.D., Marton J.P., Caloyeras J.P., Russell M.W., and Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD 3 4 (2006 Dec) 211-218
7. Campos M.A., Wanner A., Zhang G., and Sandhaus R.A. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 128 3 (2005 Sep) 1179-1186
8. Stoller J.K., Sandhaus R.A., Turino G., Dickson R., Rodgers K., and Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest 128 4 (2005 Oct) 1989-1994
9. Hill A.T., Campbell E.J., Bayley D.L., Hill S.L., and Stockley R.A. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 160 6 (1999 Dec) 1968-1975
10. McElvaney N.G., Stoller J.K., Buist A.S., Prakash U.B., Brantly M.L., Schluchter M.D., et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 111 2 (1997 Feb) 394-403
11. Needham M., and Stockley R.A. Exacerbations in {alpha}1-antitrypsin deficiency. Eur Respir J 25 6 (2005 Jun) 992-1000
12. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168 7 (2003 Oct 1) 818-900
13. Stockley R.A., Bayley D.L., Unsal I., and Dowson L.J. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 165 11 (2002 Jun 1) 1494-1498
14. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 118 5 (2000 Nov) 1480-1485
15. Campos M.A., Alazemi S., Zhang G., Sandhaus R.A., and Wanner A. Influenza vaccination in subjects with alpha1-antitrypsin deficiency. Chest 133 1 (2008 Jan) 49-55
16. Jones P.W., Quirk F.H., Baveystock C.M., and Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 6 (1992 Jun) 1321-1327
17. Ware J.E., Snow K.K., and Kosinski M. SF-36 health survey: manual and interpretation guide (2002), QualityMetric Incorporated, Lincoln, RI
18. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 2 (1987 Feb) 196-204
19. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 117 5 Suppl. 2 (2000 May) 398S-401S
20. Seersholm N., Wencker M., Banik N., Viskum K., Dirksen A., Kok-Jensen A., et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 10 10 (1997 Oct) 2260-2263
21. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 158 1 (1998 Jul) 49-59
22. Vijayasaratha K., and Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 133 1 (2008 Jan) 34-41
23. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J, doi:10.1183/09031936.00159408.
24. Aventis Behring L. Zemaira package insert. [updated 2003; cited]. Available from: (2003). http://www.fda.gov/cber/products/zemaira.htm
25. Wewers M.D., Casolaro M.A., Sellers S.E., Swayze S.C., McPhaul K.M., Wittes J.T., et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 316 17 (1987 Apr 23) 1055-1062
26. Hubbard R.C., Sellers S., Czerski D., Stephens L., and Crystal R.G. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 260 9 (1988 Sep 2) 1259-1264
27. Soy D., de la Roza C., Lara B., Esquinas C., Torres A., and Miravitlles M. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 61 12 (2006 Dec) 1059-1064